STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more

The Trump administration's most-favored nation drug pricing deals with 16 drugmakers are set to end after three years in some cases, as indicated by SEC filings. This development comes amid ongoing discussions about drug pricing and healthcare reform in the United States. In his State of the Union address, President Trump claimed that his administration had successfully reduced U.S. prescription drug costs from the highest in the world to the lowest. This assertion has sparked debate among experts and analysts regarding its accuracy, highlighting the administration's focus on drug pricing as a significant issue. In response to the evolving landscape of drug pricing and healthcare policies, pharmaceutical companies are increasing their expenditures on lobbying firms with connections to the White House. This trend reflects a broader strategy within the industry to influence policy and regulatory decisions that may impact their operations and profitability. The heightened spending on lobbying coincides with the administration's emphasis on drug pricing as a key concern. Additionally, the Trump administration has released detailed guidance aimed at facilitating the approval of bespoke medicines designed to treat individual patient mutations. This initiative is part of a broader effort to address the needs of patients with ultra-rare diseases, potentially expanding the market for pharmaceutical companies involved in developing personalized medicine. Novo Nordisk has been noted for cutting prices on its GLP-1 drugs, which are used for obesity treatment. This price reduction may be part of a competitive strategy in response to the current administration's policies and the overall changes in the healthcare market. The actions taken by both the administration and pharmaceutical companies reflect the ongoing complexities of drug pricing and healthcare reform in the United States.